Most clinicians refrain from trauma treatment for patients with psychosis because they fear symptom exacerbation and relapse. This study examined the negative side effects of trauma-focused (TF) treatment in patients with psychosis and posttraumatic stress disorder (PTSD).
INTRODUCTION
Both childhood abuse 1 and posttraumatic stress disorder (PTSD) 2, 3 are highly prevalent in individuals suffering from psychosis (CI 4.0%-20.8%). Comorbid PTSD is associated with higher symptom levels and poorer social functioning. 4 Many patients with psychosis are stuck in a vicious cycle of "instability" as long as PTSD goes untreated. 5 In clinical practice however, in this population 96.9% of the comorbid PTSD is missed. 3 In the unlikely event that PTSD is diagnosed in patients with psychotic disorders, treatment is not offered. [6] [7] [8] [9] [10] The most important harm expectancy of therapists is the fear that symptom exacerbation will destabilize the patient and result in adverse events, crisis, suicide attempts, hospitalization, revictimization, and dropout. 6, 11, 12 Tarrier and colleagues 13 reported symptom exacerbation in a proportion of trial participants who underwent imaginal exposure using the criterion of a 1-point increase in the Clinician-Administered PTSD Scale (CAPS) score; however, a later trial could not replicate these findings. 14 A recent study using a reliable change index for exacerbation found that trauma-focused (TF) treatments have a significantly lower rate of exacerbation of symptoms (both PTSD and depression) than a waiting list (WL) condition. 15 Moreover, besides symptom exacerbation, clinicians fear that TF treatments may cause dropout, 6 ,12 albeit this does not appear to be the case in general PTSD samples. 16 In addition, in several PTSD samples treatment dropout was found to be unrelated to symptom exacerbation. 11, 15 Individuals with psychotic disorders are more often revictimized than people in the general population. 17 PTSD symptoms are seen not only as a consequence of but also as a precursor of victimization and are reported to be a significant mediator in the relationship between childhood sexual abuse and revictimization, e.g. 18 However, to
date, no study has tested whether PTSD treatment influences revictimization rates.
Unfortunately, none of the above-described clinical concerns of harm-inducing TF treatments have been tested in samples with severe mental illness, such as PTSD patients with persistent psychosis, because psychosis is the most often applied exclusion criterion in PTSD trials. 19 Therefore, the present study aimed to investigate the side effects of TF treatment in patients with psychosis and to test whether trauma treatment increases symptom exacerbation, adverse events, high dropout rates and revictimization.
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METHODS
The present study is based on secondary analyses of a recently published multicenter single-blind randomized controlled trial investigating PTSD treatment in patients with a psychotic disorder. 20 The trial design was approved by the Medical Ethics Committee of the VU University Medical Center (NL:36649.029.12) and was registered at Current
Controlled Trials (ISRCTN 79584912). All participants gave written informed consent and were randomly allocated to prolonged exposure (PE) therapy (N = 53), eye movement desensitization and reprocessing (EMDR) therapy (N = 55), or WL. PE and EMDR were found to be significantly more effective than WL. Because no differences were found between the TF conditions PE and EMDR, 20 for the present study these 2 active treatment conditions were combined into one TF treatment condition (N = 108)
that was tested against a WL condition (N = 47). Participants were assessed at baseline, at posttreatment, and at 6-month follow-up. Full details of the study procedures are published elsewhere.
20,21
Participants FIGURE 1 shows the flow of participants through the trial, the dropout and loss to follow- 
Assessments

Symptom Exacerbation
Symptom exacerbation was based on change scores (from baseline to posttreatment, and from baseline to 6-mo follow-up).
The total severity score of the CAPS (range 0-136), 24 based on the frequency and intensity ratings of each of the 17 DSM-IV-TR PTSD criteria, was used to determine exacerbation of PTSD symptoms. The CAPS has excellent psychometric properties in terms of reliability and validity. 25, 26 Cutoffs for reliable exacerbation were calculated using the following formula: Cutoff = SE diff x 1.96 = SD 1 √2√(1-r) x 1.96 27, 28 where SD 1 = the standard deviation of the baseline observations in our sample (see 1) and r = the testretest reliability of the measure. The test-retest reliability for the CAPS total severity score was found to be 0.89. 29 Therefore, in our sample, the cutoff for reliable exacerbation was 14.89 points. In the present study, the assessors were successfully blinded for treatment allocation and the intraclass correlation coefficient for the CAPS was 0.81.
The Posttraumatic Stress Symptom Scale Self-Report (PSS-SR) 30 was administered to assess exacerbation of self-reported PTSD symptoms (range 0-51). In addition to the assessments at baseline, posttreatment and at 6-month follow-up, the PSS-SR was administered before each treatment session in the TF condition to assess exacerbation after the start of TF treatment and before treatment dropout. The PSS-SR has satisfactory internal consistency, high test-retest reliability and good concurrent validity, 30,31 also in a sample with a first episode of psychosis. 32 The test-retest reliability was found to be 0.83; 33 for our sample this results in a cutoff for reliable exacerbation of 9.39 points.
The Green et al. Paranoid Thought Scales (GPTS) 34 is a self-report measure that assesses paranoid ideation severity (range 32-160). The GPTS was found to be a valid measure with good internal consistency, sensitivity to clinical change, and a test-retest reliability of 0.90. 34 This results in a cutoff for reliable exacerbation of 28.79 points.
Exacerbation in severity of depressive symptoms was indexed using the BDI-II. The BDI-II has good psychometric properties regarding validity and reliability. 35 The testretest reliability was found to be 0.96, 36 resulting in a cutoff for reliable exacerbation in our sample of 6.50.
We could not calculate a reliable change index for our measure for hallucinations (i.e., the Auditory Hallucination Rating Scale; AHRS), 37 because the AHRS is not a continuous
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Participants in the TF condition rated paranoid ideation, auditory verbal hallucinations, dissociative feelings, and suicidal ideation (0-10) before and after the first 2 active TF treatment sessions, to assess exacerbation of these symptoms after the initiation of TF treatment.
Adversities
Adverse events were assessed at baseline (1-mo time-frame), at posttreatment (3 mo) and at 6-month follow-up (3 mo) by self-report into 7 types of adversities: self-harm, suicide attempt, aggressive behavior, problematic alcohol abuse, problematic drug abuse, crisis contact with mental health care, and psychiatric hospitalization.
Revictimization
Revictimization in the form of sexual abuse, physical abuse, emotional abuse (psychological maltreatment), and "other traumatic events" (eg, "In the preceding period did you experience sexual activities against your will?") 3 was assessed by self-report at baseline (1-mo time frame), at posttreatment (3 mo) and at 6-month follow-up (3 mo).
Intervention
In the TF condition participants received 8 weekly 90-min sessions of either PE 38 or Dichotomous outcomes on adverse events and revictimization were analyzed intentionto-treat (N = 155) with logistic generalized estimating equations (GEE) analyses with exchangeable correlation structure. Effects for TF versus WL were computed for "condition" (overall effect) and with interaction effects between time and condition for posttreatment (incidents during the treatment period) and for 6-month follow-up (incidents during the follow-up period). ORs from the GEE analyses are presented for all outcomes. The relative risk reduction was calculated for outcomes at posttreatment and at 6-month follow-up. Sensitivity analyses were performed in which we corrected for adverse events and revictimization at baseline.
Marked outliers with a z-score ≥3.29 in the number of adverse events data were replaced by the following formula: mean + 3.29 x SD. Nevertheless, data were still overdispersed due to an excess of zeros (eg, 54.6% reported no adversities during the treatment period)
making it impossible to perform reliable statistical analyses; therefore, only descriptives for the number of adverse events are reported RESULTS TABLE 1 presents the baseline clinical characteristics of the sample. There were no differences at baseline between the TF and the WL condition for the clinical characteristics, adversities or revictimization.
Symptom Exacerbation
Compared with WL, half as many participants in the TF condition had any form of symptom exacerbation (TABLE 2) . This effect was significant during treatment (baseline Of this subsample, 7.8% of the TF and 11.5% of the WL participants reported auditory verbal hallucinations at posttreatment, and 11.1% of the TF and 12.0% of the WL participants reported hearing voices at 6-month follow-up. No differences were found in the clinician-rated PTSD-symptoms and depression.
The active TF treatment started in the second session. To investigate whether either the anticipation or initiation of active TF treatment was associated with an exacerbation of PTSD symptoms, we calculated PSS-SR change scores for the start of the first session to the start of the second session (anticipation) and from the second session to the third session (after initiation of TF treatment) in the participants with data for these sessions.
Anticipating the start of TF treatment 7 participants (7.1%) had reliable PTSD symptom exacerbation, 84 (85.7%) had stabile PTSD symptom severity, and 7 (7.1%) showed reliable improvement in PTSD symptoms. After the initiation of TF treatment 1.1%
showed symptom exacerbation, 87.2% had stabile symptom severity, and 11.7% showed an improvement in PTSD symptoms. · 92 · ideation and suicidality decreased significantly during the first TF session, and paranoid ideation and dissociative feelings decreased during the second TF session.
Dropout
The relationship between symptom exacerbation and treatment dropout was tested in the 91 (84.3%) participants in the TF condition that attended the posttreatment assessment. Nine of these participants (9.9%) dropped out of treatment. The 13 participants with reliable exacerbation of any symptoms (TABLE 2) did not dropout more often than the 78 participants without exacerbation, χ² (1, n = 91) = 0.05, P = .611, phi = -0.08. However, this analysis was based on data of only 9 of the 24 treatment dropouts (the remaining participants missed the posttreatment assessment). It is possible that several of the 15 dropouts that were lost to follow-up, dropped out of treatment due to 
0.00
Note: Abbreviations are explained in the rst footnote to TABLE 1. χ², chi-square test value; df, degrees of freedom; PTSD, posttraumatic stress disorder. a One participant withdrew from further participation a er completing CAPS and PSS-SR at 6-mo follow-up. erefore, at 6-mo follow-up N = 40 for CAPS and PSS-SR and N = 39 for the GPTS and BDI-II. b Any exacerbation on CAPS, PSS-SR, GPTS, or BDI-II. c We repeated the analyses with lower cuto s for exacerbation, ie, not multiplying symptom exacerbation by 1.96, because other studies used these lower cuto s for exacerbation. 11, 15 All the results for the analyses with lower cuto s for exacerbation (not reported) were similar to the analyses reported here. e only di erence is that there was signi cantly less lower cuto exacerbation of paranoid ideations (GPTS) in the trauma-focused condition during the treatment period (P = .008; phi =−0.26). symptom exacerbation. Moreover, because causality is unclear in the previous analysis, we analyzed the PSS-SR session data of the 24 treatment dropouts of whom 9 never started treatment and 15 actually dropped out during treatment and provided session data. For these 15 participants we compared the PSS-SR score for the last attended treatment session with the baseline PSS-SR score using the reliable change criterion of 9.39 points. Prior to dropout, 2 participants (13.3%) showed reliable exacerbation of PTSD symptoms, 7 (46.7%) showed no reliable change, and 6 participants (40.0%)
showed reliable improvement in PTSD symptoms. These results show that, in this sample, dropout appeared to be unrelated to symptom exacerbation.
Adverse Events 
Revictimization
Percentages of revictimization are presented in FIGURE 2b. Participants that received TF treatment were significantly less likely to experience revictimization than participants with TF, twice as many participants in the WL condition showed some form of symptom exacerbation. Exacerbation of self-rated PTSD (0.0%-3.4%) and paranoia symptoms (2.3%-3.3%) was extremely rare in TF. Exacerbation of depressive symptoms was more common in TF (8.0%-9.9%), but comparable with WL (7.7%-17.9%). In this sample, PTSD symptom exacerbation in anticipation of TF treatment was rare (7.1%) and after the initiation of TF treatment, PTSD symptom exacerbation was virtually absent (1.1%). Moreover, treatment dropout did not appear to be related to PTSD symptom exacerbation. In the first 2 TF treatment sessions there was no exacerbation of auditory verbal hallucinations, dissociative feelings, or suicidal ideation, and especially paranoid ideation significantly decreased. Fewer participants in TF than in WL experienced an adverse event (relative risk reduction = 27.9%-34.6%). On average, patients in TF experienced half as many adverse incidents compared with those in WL. Participants receiving TF were also less likely to be revictimized during follow-up (relative risk reduction =80.3%). The reduction of revictimization during follow-up was significantly associated with a reduction in PTSD symptoms (especially re-experiencing symptoms), during the treatment period.
Similar to studies in general PTSD samples 11, 14, 15 we found that guideline TF treatments with exposure to trauma memories did not induce symptom exacerbation. These findings are in contrast to the beliefs held by most clinicians about negative side effects of TF. 6, 7 The dropout rate in the present study (22.2%) was comparable with previous studies, 16 and the fact that dropout was unrelated to symptom exacerbation is in line with studies in general PTSD samples. 11, 15 Adversities are common in this population. TF appears to reduce adversities; this is in line with previous findings that TF treatment is not only effective in reducing PTSD symptoms, but has additional value concerning reduction of related psychopathology, such as depression and social functioning (for a review see 40 ).
To our knowledge, this is the first study to report on the direct influence of TF treatment on revictimization, which is a significant problem in persons with persistent psychosis and other severe mental illnesses. 5, 17 The fact that a reduction in PTSD symptoms was associated with less revictimization suggests that effectively treating PTSD may safeguard individuals from revictimization. This is in line with studies reporting that PTSD mediates the relationship between childhood abuse and revictimization. 18 It
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The present study has some limitations. First, adverse events and revictimization were self-rated; however, people with psychosis have been found to be reliable respondents on these matters. 41 Second, "treatment as usual" for psychosis varies between countries.
In the present trial participants received multidisciplinary care for psychosis in community mental health teams. Although we included a large sample, some effects may not have reached significance due to the small numbers of events. Also, although replication of our findings is warranted, the direction of all outcomes is consistent, i.e., negative incidents tended to occur less often in the TF condition.
The study also has several strengths. These include (1) Effectively treating PTSD in these patients with severe and complex symptom patterns, may be a highly efficient way to break the vicious cycles faced by many traumatized people and also reduce the need for mental health care. 5 We conclude that patients with psychosis and PTSD can safely undergo TF treatment. Not only may PTSD symptoms be ameliorated, but also adverse events and revictimization experiences might be prevented. TF treatment appears to have important positive side
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